180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, is reporting on its clinical pharmacology study designed to evaluate the uptake of cannabidiol (“CBD”) in a solid formulation that can be delivered as a pill. According to the report, the clinical trial, which was performed with Professor Avi Domb of the Hebrew University, School of Pharmacy, and Professor Elyad Davidson of Hadassah Hospital, involved 12 human participants and compared two solid formulations of CBD with Epidiolex, a U.S. Food and Drug Administration (“FDA”)-approved drug for epilepsy. The company noted that CBD has shown promise in studies on treatment of pain, post-traumatic stress disorder (“PTSD”), head trauma and other indications. However, the oral liquid delivery is not ideal, and the formulations tested by 180 Life Sciences and its collaborators in this study show potential for CBD being delivered by mouth in capsule or pill form. The company is waiting for full results from the study. “If shown via further clinical testing, 180 Life Sciences’ proprietary solid formulation for the delivery of CBD may provide medical professionals with greatly expanded options to prescribe and deliver CBD in a precisely dosed, high-uptake pill format rather than the current liquid format,” said Professor Avi Domb in the press release. “This may have potentially significant commercial market potential by avoiding the complexity associated with unpredictable liquid formulation delivery. Both physicians and patients may have broader acceptance of a solid oral pill format.”
To view the full press release, visit https://ibn.fm/tKhcE
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research and, where appropriate, combination therapy. For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
